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Increasing evidence suggests that the second messenger
cGMP plays a central role in health and disease, but the
downstream mechanisms of cGMP-dependent signaling
are not well understood. The cGMP-dependent protein
kinase type I (cGKI) is an attractive candidate mediator of
cGMP signaling, but the pharmacological analysis of cGKI
function is limited by the lack of highly specific cGKI acti-
vators and inhibitors. To study the (patho)physiological
roles of cGKI in vivo, conventional and conditional cGKI
knockout mouse models have been established. Whereas
cGKI null mutants have a decreased life span (50% of
these mice die before 5 to 6 weeks of age), tissue-specific
mutants lacking cGKI selectively in the cerebellum, hip-
pocampus, cardiomyocytes, or smooth muscle cells are
fully viable allowing one to perform long-term experi-
ments and to study the cell type-specific role of cGKI in
adult animals. The analysis of cGKI-deficient mouse mod-
els showed that this protein kinase contributes to many
(but not all) effects of cGMP in the cardiovascular, gas-
trointestinal, and nervous system. For instance, cGKI is
involved in the acute regulation of smooth muscle tone
and platelet aggregation, but is most likely not essential
for basal blood pressure control. Of particular interest,
cGKI signaling contributes to long-lasting changes in neu-
ronal plasticity, ranging from axonal pathfinding during
embryogenesis to the adaptation of synaptic activity dur-
ing learning and nociception.
These findings led to the speculation that cGKI might also
regulate the 'plastic' processes associated with the pheno-
typic modulation of vascular smooth muscle cells (SMCs)
during pathological vascular remodeling. To test this
hypothesis, we have developed a tamoxifen-inducible
Cre/lox system which allows one to induce somatic cGKI
mutations selectively in SMCs of adult mice and to follow
the fate of wild-type and cGKI-deficient SMCs during vas-
cular remodeling. Our data indicate that a signaling path-
way via cGMP and cGKI promotes the generation of SMCs
with increased growth potential in vivo and in vitro, per-
haps via effects on proliferation, apoptosis, and cytoskel-
etal dynamics. Thus, cGMP/cGKI signaling in vascular
SMCs might promote pathological vascular remodeling
processes, such as atherogenesis. Chronic activation of
this pathway by cGMP-elevating drugs (e.g. organic
nitrates, sildenafil) might result in undesired side effects,
whereas its inhibition (e.g. by a cGKI inhibitor) might be
an interesting approach to treat atherosclerosis.
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